Blood test may reveal how lung cancer patients respond to immunotherapy

NCT ID NCT06823401

Recruiting now Knowledge-focused Sponsor: Fondazione Ricerca Traslazionale Source: ClinicalTrials.gov ↗

First seen Feb 06, 2026 · Last updated May 14, 2026 · Updated 14 times

Summary

This study is for adults with non-small cell lung cancer (NSCLC) who are about to start immunotherapy. Researchers want to understand how the body makes antibodies against the immunotherapy drugs themselves. By analyzing blood samples from 270 participants, they hope to learn more about why some people respond better to treatment than others. This is an observational study, not a treatment trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Istituto Tumori Regina Elena
ENROLLING_BY_INVITATION

Roma, RM, 000144, Italy
Istituto Tumori Regina Elena
RECRUITING

Roma, RM, 00128, Italy

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

NSCLC